Abstract
Droloxifene (3-hydroxytamoxifen citrate) is a new synthetic non-steroidal antiestrogen which has been developed with high receptor binding affinity and possibly improved antiestrogenic activity in man. Recently, hormone receptors were observed in human colorectal carcinoma cell lines. For this reason, we treated 24 patients with advanced colorectal carcinoma and progressive disease with Droloxifen in a Phase-II trial. All patients exept three had been pretreated by cyto-toxic chemotherapy. The dose of Droloxifene was 100 mg orally/day for at least eight weeks. Fifteen patients were evaluable for response. No complete or partial remission was observed. However, there were six patients (40%) showing tumor stabilization. The time to progression was twelve to 29 weeks. The toxicity of treatment was low and consisted of only few episodes of nausea, constipation and pain. The data suggest that Droloxifene has marginal activity for treatment of colorectal carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
